201 related articles for article (PubMed ID: 34885129)
1. Adapting Imaging Protocols for PET-CT and PET-MRI for Immunotherapy Monitoring.
Beuthien-Baumann B; Sachpekidis C; Gnirs R; Sedlaczek O
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885129
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study.
Paspulati RM; Partovi S; Herrmann KA; Krishnamurthi S; Delaney CP; Nguyen NC
Abdom Imaging; 2015 Aug; 40(6):1415-25. PubMed ID: 26112492
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
5. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
6. Future image acquisition trends for PET/MRI.
Boss A; Weiger M; Wiesinger F
Semin Nucl Med; 2015 May; 45(3):201-11. PubMed ID: 25841275
[TBL] [Abstract][Full Text] [Related]
7. [PET/MRI].
Beuthien-Baumann B
Radiologe; 2018 Mar; 58(3):211-217. PubMed ID: 29379990
[TBL] [Abstract][Full Text] [Related]
8. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
9.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
10. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.
Grueneisen J; Nagarajah J; Buchbender C; Hoffmann O; Schaarschmidt BM; Poeppel T; Forsting M; Quick HH; Umutlu L; Kinner S
Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367
[TBL] [Abstract][Full Text] [Related]
11. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
[TBL] [Abstract][Full Text] [Related]
12. Multimodal imaging approaches: PET/CT and PET/MRI.
Pichler BJ; Judenhofer MS; Pfannenberg C
Handb Exp Pharmacol; 2008; (185 Pt 1):109-32. PubMed ID: 18626801
[TBL] [Abstract][Full Text] [Related]
13. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
Chavdarova LI; Tzonevska AD; Piperkova EN
Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Value of FDG PET/MRI in Females With Pelvic Malignancy-A Systematic Review of the Literature.
Nguyen NC; Beriwal S; Moon CH; D'Ardenne N; Mountz JM; Furlan A; Muthukrishnan A; Rangaswamy B
Front Oncol; 2020; 10():519440. PubMed ID: 33123460
[TBL] [Abstract][Full Text] [Related]
15. Comparison of
Ling SW; de Jong AC; Schoots IG; Nasserinejad K; Busstra MB; van der Veldt AAM; Brabander T
Eur Urol Open Sci; 2021 Nov; 33():61-71. PubMed ID: 34632423
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI.
Seemann MD; Meisetschlaeger G; Gaa J; Rummeny EJ
Eur J Med Res; 2006 Feb; 11(2):58-65. PubMed ID: 16504962
[TBL] [Abstract][Full Text] [Related]
17. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients.
Spick C; Herrmann K; Czernin J
J Nucl Med; 2016 Mar; 57(3):420-30. PubMed ID: 26742709
[TBL] [Abstract][Full Text] [Related]
19. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
20. Applications of PET/MRI in Abdominopelvic Oncology.
Galgano SJ; Calderone CE; Xie C; Smith EN; Porter KK; McConathy JE
Radiographics; 2021 Oct; 41(6):1750-1765. PubMed ID: 34597228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
